Back to top
more

Haemonetics (HAE)

(Delayed Data from NYSE)

$76.15 USD

76.15
421,444

+0.21 (0.28%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $76.11 -0.04 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

AMN Healthcare (AMN) to Report Q1 Earnings: What's in Store?

AMN Healthcare's (AMN) first-quarter results are likely to reflect solid demand in some of the areas of its business.

DENTSPLY SIRONA (XRAY) to Post Q1 Earnings: What's in Store?

DENTSPLY SIRONA's (XRAY) first-quarter results are likely to reflect strong performance at Technologies & Equipment business.

McKesson (MCK) to Report Q4 Earnings: What's in the Cards?

McKesson's (MCK) fiscal fourth-quarter results are likely to reflect the solid show by the U.S. Pharmaceutical and Specialty Solutions segment.

PerkinElmer (PKI) to Post Q1 Earnings: What's in the Cards?

PerkinElmer's (PKI) first-quarter results are likely to reflect strong performance at the Diagnostics segment.

AmerisourceBergen (ABC) to Post Q2 Earnings: What's in Store?

AmerisourceBergen's (ABC) fiscal second-quarter results are likely to reflect solid performance at the U.S. Healthcare Solutions segment.

What's in Store for West Pharmaceutical's (WST) Q1 Earnings?

West Pharmaceutical's (WST) first-quarter results are likely to reflect strength in the Proprietary Products business.

DexCom (DXCM) to Report Q1 Earnings: What's in the Cards?

DexCom's (DXCM) first-quarter results are likely to reflect rising global awareness of its real-time CGM.

Stryker (SYK) to Report Q1 Earnings: What's in the Cards?

Stryker's (SYK) first-quarter results are likely to reflect strong segmental performances.

Baxter (BAX) to Report Q1 Earnings: What's in the Offing?

Baxter's (BAX) first-quarter results are likely to reflect growth in its Acute Therapies business.

What's in Store for Intuitive Surgical's (ISRG) Q1 Earnings?

Intuitive Surgical's (ISRG) first-quarter results are likely to reflect solid performance in the Instruments & Accessories segment.

Here's Why You Should Hold on to Haemonetics (HAE) For Now

Investors are optimistic about Haemonetics (HAE) given the strength in its Hemostasis Management franchise and increased product uptake.

Haemonetics' (HAE) Hospital Business Grows, Cost Ails Stay

Haemonetics (HAE) has made the NexSys PCS devices available in the United States to ensure timely conversion of the remainder of its major customers to the same by mid-fiscal 2023.

Haemonetics (HAE) Up 4.4% Since Last Earnings Report: Can It Continue?

Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Retain Haemonetics (HAE) Stock for Now

Investors are optimistic about Haemonetics (HAE) given strong recovery across businesses and strength in plasma franchise.

Haemonetics (HAE) Q3 Earnings Top Estimates, Revenues Miss

Haemonetics (HAE) exited the fiscal third quarter with better-than-expected earnings and robust growth across Hospital business, driving the top line.

Haemonetics (HAE) Q3 Earnings Beat Estimates

Haemonetics (HAE) delivered earnings and revenue surprises of 12% and 2.58%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Should You Buy Haemonetics (HAE) Ahead of Earnings?

Haemonetics (HAE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Haemonetics (HAE) Expected to Beat Earnings Estimates: Should You Buy?

Haemonetics (HAE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why You Should Retain Haemonetics (HAE) Stocks for Now

Investors are optimistic about Haemonetics (HAE) on a strong recovery across businesses, mainly at Hospital, and the initial Plasma Persona rollouts.

Haemonetics (HAE) Q2 Earnings Lag Estimates, Gross Margin Grows

Haemonetics (HAE) revenues increased year over year in the fiscal second quarter, supported by recovery across major businesses, especially Hospital and the initial Plasma Persona rollouts.

Haemonetics (HAE) Lags Q2 Earnings and Revenue Estimates

Haemonetics (HAE) delivered earnings and revenue surprises of -4.76% and -2.44%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Haemonetics (HAE) Earnings Expected to Grow: Should You Buy?

Haemonetics (HAE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why You Should Retain Haemonetics (HAE) Stock for Now

Investors are optimistic about Haemonetics (HAE) on strong demand for NexSys PCS system and potential of Hemostasis Management franchise.

Haemonetics (HAE) Rides on Plasma Arm Recovery Amid COVID Woes

Haemonetics' (HAE) hospital business is recovering primarily driven by continued improvement in hospital procedures.

Why Is Haemonetics (HAE) Up 4.9% Since Last Earnings Report?

Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.